Paper Details

  1. Home
  2. Paper Details

Edoxaban versus warfarin in patients with atrial fibrillation.

Author: , AntmanElliott M, BetcherJoshua, BraunwaldEugene, EzekowitzMichael D, GiuglianoRobert P, GripLaura T, HalperinJonathan L, HanyokJames J, KoretsuneYukihiro, MercuriMichele, MurphySabina A, PatelIndravadan, PatelShirali P, RudaMikhail, RuffChristian T, RuzylloWitold, ShiMinggao, WaldoAlbert L, WeitzJeffrey I, WiviottStephen D, ŠpinarJindřich

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized controlled trial compared two once-daily regimens of edoxaban, a direct oral factor Xa inhibitor, with warfarin in patients with moderate-to-high-risk atrial fibrillation. The study found that both edoxaban regimens were noninferior to warfarin in preventing stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1310907

データ提供：米国国立医学図書館（NLM）

Edoxaban vs. Warfarin: A Head-to-Head Comparison in Atrial Fibrillation

Atrial fibrillation, a type of irregular heartbeat, increases the risk of stroke. This study compares the effectiveness and safety of edoxaban, a newer oral anticoagulant, to warfarin, the traditional standard of care, in patients with atrial fibrillation.

A Large-Scale Trial: Edoxaban's Promise

The researchers conducted a massive randomized, double-blind, double-dummy trial involving over 21,000 patients with atrial fibrillation. This is akin to conducting a vast expedition across the desert, meticulously comparing the results of different routes and strategies. The findings showed that edoxaban was non-inferior to warfarin in preventing stroke or systemic embolism, while significantly reducing the risk of bleeding and death from cardiovascular causes.

A Potential Shift in Anticoagulation Treatment

The study suggests that edoxaban may offer a promising new alternative to warfarin for preventing stroke in patients with atrial fibrillation, particularly those with moderate-to-high risk. This is like discovering a new and efficient camel breed that can navigate the desert with greater speed and endurance, leading to improved outcomes and reduced travel time.

Dr. Camel's Conclusion

The study provides compelling evidence supporting edoxaban as a safe and effective alternative to warfarin for patients with atrial fibrillation. This research may lead to a shift in the landscape of anticoagulation treatment, offering a new and improved route for preventing stroke and improving cardiovascular health.
Date :
  1. Date Completed 2013-12-16
  2. Date Revised 2023-01-20
Further Info :

Pubmed ID

24251359

DOI: Digital Object Identifier

10.1056/NEJMoa1310907

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.